SAN DIEGO, April 07, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Viatris Inc. (NASDAQ: VTRS) securities between August 8, 2024 and February 26, 2025, inclusive (the “Class Period”), have until June 3, 2025 to seek appointment as lead plaintiff of the Viatris class action lawsuit. Captioned Quinn v. Viatris Inc., No. 25-cv-00466 (W.D. Pa.), the Viatris class action lawsuit charges Viatris and certain of Viatris’ top executives with viola ...

Core Viewpoint - Viatris Inc. has reached a nationwide settlement framework to resolve opioid-related claims, agreeing to pay up to $335 million over nine years to support state and local efforts addressing opioid issues, while maintaining that this settlement does not imply any admission of wrongdoing or liability [1][2]. Group 1: Settlement Details - The settlement amount could reach a maximum of $335 million, with annual payments ranging from approximately $27.5 million to $40 million over a nine-year period [2]. - The company had already accrued an estimate for this potential settlement, which is reflected in its annual report for the year ended December 31, 2024 [2]. Group 2: Commitment to Public Health - The company continues to work on solutions for public health challenges, including manufacturing a generic injectable version of naloxone, a drug for overdose reversal, and a generic buprenorphine/naloxone product for opioid addiction treatment [3]. - Viatris is also developing a novel delivery method for meloxicam, a non-opioid pain medication [3]. Group 3: Company Mission and Operations - The settlement allows the company to focus on its mission of empowering people to live healthier lives and to address unmet patient needs through an expanded innovative portfolio [4]. - Viatris serves approximately 1 billion patients annually with its diverse portfolio of medicines, emphasizing its commitment to global healthcare [4][5].

Core Viewpoint - A class action lawsuit has been filed against Viatris Inc. for alleged violations of federal securities laws related to misleading information about the company's operations and regulatory issues [1][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased Viatris securities between August 8, 2024, and February 26, 2025, inclusive [2]. - The Complaint alleges that Viatris misrepresented the impact of a warning letter issued by the FDA regarding its Indore, India facility, downplaying it as a "minor headwind" [3]. Group 2: Next Steps - Investors who suffered losses in Viatris have until June 3, 2025, to request to be appointed as lead plaintiff in the case [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - The law firm operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. - Bronstein, Gewirtz & Grossman, LLC is recognized for representing investors in securities fraud class actions and has recovered significant amounts for investors [6].

NEW YORK , April 3, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Viatris Inc. (NASDAQ: VTRS) resulting from allegations that Viatris may have issued materially misleading business information to the investing public.So What: If you purchased Viatris securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen La ...

Group 1 - Viatris Inc. will report its first quarter 2025 financial results on May 8, 2025, with a webcast scheduled for 8:30 a.m. ET to discuss the results [1] - The company invites investors and the public to listen to the live webcast, which can be accessed via their website or by phone [1] Group 2 - Viatris is a global healthcare company that combines generics and brand medicines to address healthcare needs worldwide [2] - The company aims to empower people to live healthier lives, providing access to high-quality medicines for approximately 1 billion patients annually [2] - Viatris has a diverse portfolio of medicines and a global supply chain designed to reach patients effectively [2] - The company is headquartered in the U.S. with global centers in Pittsburgh, Shanghai, and Hyderabad, India [2]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Viatris To Contact Him Directly To Discuss Their Options If you suffered significant losses in Viatris stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a le ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Viatris Inc. due to allegations of materially misleading business information issued by the company [1] Group 1: Legal Action and Investor Rights - Investors who purchased Viatris securities may be entitled to compensation through a class action without any out-of-pocket fees, facilitated by a contingency fee arrangement [2] - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to Viatris [2] Group 2: Financial Impact and Company Announcement - On February 27, 2025, Viatris announced its fourth quarter and full year 2024 financial results, revealing a warning letter and import alert from the FDA affecting 11 products, including lenalidomide and everolimus [3] - The company anticipates a negative impact of approximately $500 million on total revenues and about $385 million on adjusted EBITDA for 2025 due to the FDA's actions [3] - Following this announcement, Viatris stock price fell by 15.2% on February 27, 2025 [3] Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]

NEW YORK, March 18, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Viatris Inc. (NASDAQ: VTRS) resulting from allegations that Viatris may have issued materially misleading business information to the investing public.So What: If you purchased Viatris securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Ros ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Viatris To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Viatris stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]NEW YORK, March 13, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading n ...

Company Overview - Viatris Inc. is a global healthcare company that bridges the gap between generics and brands, aiming to address healthcare needs worldwide [2] - The company provides access to high-quality medicines for approximately 1 billion patients annually, covering all stages of life and various health conditions [2] - Viatris has a diverse portfolio of medicines and a unique global supply chain designed to reach patients effectively [2] Upcoming Event - Viatris will present at the Barclays 27th Annual Global Healthcare Conference on March 11, 2025, at 2 p.m. ET [1] - A live webcast of the event will be available, with an archived version accessible for a limited time after the event [1]